M&R Capital Management Inc. lifted its holdings in shares of Baxter International Inc (NYSE:BAX) by 2.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 14,230 shares of the medical instruments supplier’s stock after buying an additional 400 shares during the quarter. M&R Capital Management Inc.’s holdings in Baxter International were worth $1,165,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in shares of Baxter International by 1.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,205,779 shares of the medical instruments supplier’s stock valued at $79,362,000 after purchasing an additional 17,633 shares during the last quarter. Archford Capital Strategies LLC grew its holdings in shares of Baxter International by 60.0% during the 1st quarter. Archford Capital Strategies LLC now owns 800 shares of the medical instruments supplier’s stock valued at $65,000 after purchasing an additional 300 shares during the last quarter. Evolution Wealth Advisors LLC bought a new position in shares of Baxter International during the 2nd quarter valued at $32,000. Round Table Services LLC grew its holdings in shares of Baxter International by 19.9% during the 1st quarter. Round Table Services LLC now owns 4,015 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 666 shares during the last quarter. Finally, Diversified Trust Co grew its holdings in shares of Baxter International by 17.8% during the 1st quarter. Diversified Trust Co now owns 42,508 shares of the medical instruments supplier’s stock valued at $3,456,000 after purchasing an additional 6,420 shares during the last quarter. 83.87% of the stock is currently owned by institutional investors.
Shares of Baxter International stock traded down $0.38 during trading on Friday, hitting $84.70. The company’s stock had a trading volume of 1,573,832 shares, compared to its average volume of 2,310,100. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 1.30. The business’s fifty day moving average price is $82.31. The firm has a market capitalization of $43.44 billion, a P/E ratio of 27.77, a PEG ratio of 1.97 and a beta of 1.00. Baxter International Inc has a 52 week low of $61.05 and a 52 week high of $86.65.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Investors of record on Friday, August 30th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.04%. The ex-dividend date is Thursday, August 29th. Baxter International’s payout ratio is 28.85%.
In related news, SVP Jacqueline Kunzler sold 593 shares of the firm’s stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $80.46, for a total value of $47,712.78. Following the transaction, the senior vice president now owns 9,023 shares of the company’s stock, valued at $725,990.58. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Third Point Llc sold 5,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $76.37, for a total transaction of $381,850,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 5,001,913 shares of company stock worth $382,000,950. 0.70% of the stock is currently owned by insiders.
Several research firms recently commented on BAX. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Friday, June 21st. Cowen set a $75.00 price target on shares of Baxter International and gave the company a “hold” rating in a research report on Monday, April 22nd. Barclays set a $82.00 price target on shares of Baxter International and gave the company a “hold” rating in a research report on Friday, July 26th. JPMorgan Chase & Co. increased their price target on shares of Baxter International from $80.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, May 13th. Finally, Credit Suisse Group increased their price target on shares of Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $85.27.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: What is a balanced fund?
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.